Scroll
To Top
0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

*Important

The information contained in the Organizational Database (ODB) is provided for informational purposes only. There is no implied endorsement by NORD. NORD does not promote or endorse participation in any specific organization. The information is subject to change without notice. Every effort is made to ensure that the details for each entry are as current as possible.


A Cure in Sight


Address

9500 Euclid Avenue
Cleveland, OH

Email Address

melody@acureinsight.org

Description

A Cure In Sight™ is an IRS approved 501 C(3) organization, EIN 46-1274306,  founded to raise ocular melanoma awareness and to help those with ocular melanoma find and pay for the treatments that they need. Ocular melanoma is a rare eye cancer that develops in the melanocytes of the eye’s choroid, iris or ciliary body.

While the initial tumor is nearly always treatable, about 50% of patients will develop fatal metastases. Currently, there is no cure for metastatic ocular melanoma. However, promising evidence exists that early detection, genetic analysis, targeted treatment, and integrative therapy may guarantee better results.

Please Note

The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and the credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions is strictly prohibited.

NORD's Rare Disease Information Database is copyrighted and may not be published without the written consent of NORD.